Skip to main content
Clinical Trials/NCT05776446
NCT05776446
Completed
Not Applicable

Retrospective Study on the Clinical Behavior of the Asqelio™ Trifocal Diffractive Intraocular Lens With Follow-up at 3 Months

AST Products, Inc.1 site in 1 country25 target enrollmentMay 27, 2022
ConditionsCataract

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cataract
Sponsor
AST Products, Inc.
Enrollment
25
Locations
1
Primary Endpoint
Best-corrected distance visual acuity
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The main objective of this study was to evaluate distance, intermediate, and near vision in patients who have undergone cataract extraction with bilateral implantation of a new hydrophobic trifocal diffractive intraocular lens (IOL) with a biospheric design, the Asqelio Trifocal IOL (AST Products, Inc., Billerica MA, USA), along with patient-reported outcomes (PRO). For that purpose the clinical information of 50 eyes from 25 patients was retrospectively analyzed 3 months after implantation

Registry
clinicaltrials.gov
Start Date
May 27, 2022
End Date
September 1, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 50 years or older submitted to cataract surgery with binocular implantation of Asqelio Trifocal TFLIO130C IOL
  • Seeking spectacle independence after surgery
  • IOL power between +5.0D y +34.0D
  • Transparent ocular media, except for the cataract prior to surgery.
  • Potential postoperatory visual acuity of 20/25 or better, as assessed prior to surgery

Exclusion Criteria

  • Preoperatory corneal astigmatism greater than 1.0D
  • Previous corneal surgery or trauma
  • Irregular cornea (e.g. keratoconus)
  • Choroidal hemorrhage
  • Microftalmos
  • Severe corneal dystrophy
  • Uncontrolled or medically controlled glaucoma
  • Clinically significant macular changes
  • Severe concomitant ocular condition
  • Cataract not age-related

Outcomes

Primary Outcomes

Best-corrected distance visual acuity

Time Frame: 3 months after implantation

Best-corrected visual acuity for distance (4m) determined under photopic conditions using EDTRS optotypes, in LogMAR units

Defocus curve

Time Frame: 3 months after implantation

Binocular defocus curve with best correction for distance obtained varying mergence from -4.0D to +2.0D in 0.5D steps

Uncorrected distance visual acuity

Time Frame: 3 months after implantation

Uncorrected visual acuity for distance (4m) determined under photopic conditions using EDTRS optotypes, in LogMAR units

Uncorrected intermediate visual acuity

Time Frame: 3 months after implantation

Uncorrected visual acuity for intermediate disntace (60cm) determined under photopic conditions using EDTRS optotypes, in LogMAR units

Distance-corrected near visual acuity

Time Frame: 3 months after implantation

Distance-corrected visual acuity for near (40cm) determined under photopic conditions using EDTRS optotypes, in LogMAR units

Uncorrected near visual acuity

Time Frame: 3 months after implantation

Uncorrected visual acuity for near (40cm) determined under photopic conditions using EDTRS optotypes, in LogMAR units

Distance-corrected intermediate visual acuity

Time Frame: 3 months after implantation

Distance-corrected visual acuity for intermediate disntace (60cm) determined under photopic conditions using EDTRS optotypes, in LogMAR units

Secondary Outcomes

  • Manifest Refraction(Preoperatively and 3 months after implantation)
  • Adverse events(3 months after implantation)
  • Patient-reported outcomes CATQuest9SF(3 months after implantation)
  • Patient-reported outcomes PRSIQ(3 months after implantation)
  • Patient-reported outcomes PRVSQ(3 months after implantation)

Study Sites (1)

Loading locations...

Similar Trials